Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH
- Written by PR Newswire
SHANGHAI, Jan. 19, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today reported positive top-line results from the Phase 2a RISE clinical trial of HPG1860, a next generation non-bile acid, liver selective farnesoid X...














